Treatment
Potential advantage of magnetic resonance imaging in detecting thoracic wall infiltration in pleural mesothelioma: A retrospective single-center analysis
JTCVS Open 2024 October 22 [Link] Isabel Barreto, Sabine Franckenberg, Thomas Frauenfelder, Isabelle Opitz, Olivia Lauk Abstract Objectives: Thoracic wall infiltration in pleural mesothelioma determines the extent of resection and can be an important prognostic factor. Currently, standardized imaging for restaging after neoadjuvant systemic therapy comprises contrast-enhanced computed tomography or positron emission tomography. Additional thoracic…
Read MoreImpact of Neoadjuvant and Adjuvant Pleural Intensity-Modulated Radiotherapy in Multimodality Treatment for Malignant Pleural Mesothelioma
Thoracic Cancer 2025 March [Link] Berta Mosleh, Stefan Schwarz, Anna Cho, Katharina Sinn, Ariane Steindl, Sabine Zöchbauer-Müller, Wolfgang J Köstler, Karin Dieckmann, Martin Heilmann, Joachim Widder, Daniela Gompelmann, Clemens Aigner, Thomas Klikovits, Mir Alireza Hoda Abstract Background: Few malignancies provoke as many controversies about treatment as pleural mesothelioma. There is limited experience with novel radiotherapy…
Read MoreCurrent and Future Perspective of PET/CT in Response Assessment of Malignant Pleural Mesothelioma
Seminars in Nuclear Medicine 2025 March [Link] Manar Badarna, Zohar Keidar, Elite Arnon-Sheleg Abstract Malignant pleural mesothelioma (MPM) is a rare but aggressive cancer characterized by its unique growth patterns, presenting substantial diagnostic challenges. With the shift toward immunotherapy for MPM treatment, assessing therapeutic responses has become increasingly complex. Recent studies indicate that FDG PET/CT…
Read MoremiRNA-503 inhibition exerts anticancer effects and reduces tumor growth in mesothelioma
Journal of Experimental & Clinical Cancer Research 2025 February 22 [Link] Miriam Piccioni, Francesco Di Meo, Anna Valentino, Virginia Campani, Maddalena Arigoni, Mirella Tanori, Mariateresa Mancuso, Rossana Cuciniello, Marco Tomasetti, Federica Monaco, Gaia Goteri, Enrico P Spugnini, Raffaele A Calogero, Giuseppe De Rosa, Gianfranco Peluso, Alfonso Baldi, Stefania Crispi Abstract Background: Malignant mesothelioma (MM) is…
Read MoreCD276 as a critical independent biomarker and immune checkpoint inhibitor target in epithelioid mesothelioma-TCGA study
Journal of Thoracic Disease 2025 January 24 [Link] Yuko Aoki, Ken Arimura, Kenzo Hiroshima, Yasuto Sato, Mitsuko Kondo, Etsuko Tagaya Abstract Background: CD276 is an immune checkpoint, and immune checkpoint inhibitors (ICIs) targeting CD276 have been tested against various cancers. However, the precise role of CD276 in mesothelioma subtypes is unknown. This study aimed to…
Read MoreDNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy
Journal of Experimental & Clinical Cancer Research 2025 February 18 [Link] Maria Fortunata Lofiego, Rossella Tufano, Emma Bello, Laura Solmonese, Francesco Marzani, Francesca Piazzini, Fabrizio Celesti, Francesca Pia Caruso, Teresa Maria Rosaria Noviello, Roberta Mortarini, Andrea Anichini, Michele Ceccarelli, Luana Calabrò, Michele Maio, Sandra Coral, Anna Maria Di Giacomo, Alessia Covre Abstract Background: Co-targeting of…
Read MorePrognostic importance of the neutrophil-to-lymphocyte ratio in malignant peritoneal mesothelioma patients receiving cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
BMC Cancer 2025 February 14 [Link] Zhang Xinjing, Gong Lei, Li Xinbao, Ji Zhonghe, Yang Zhiran, Gao Chao, Zhang Kai, Yan Lijun, Yan Guojun, Yu Junhui, Zhang Yanbin, An Songlin Abstract Background: Malignant peritoneal mesothelioma (MPM) is a rare but aggressive cancer. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) was the preferred choice for…
Read MoreA Meta-Analysis of First-Line Treatments for Unresectable Pleural Mesothelioma: Indirect Comparisons from Reconstructed Individual Patient Data of Six Randomized Controlled Trials
Cancers 2025 February 3 [Link] Andrea Messori, Sabrina Trippoli, Eugenia Piragine, Sara Veneziano, Vincenzo Calderone Abstract Background: In unresectable pleural mesothelioma, pemetrexed+cisplatin as first line is considered the standard of care, but novel treatments have been recently proposed. Methods: Our objective was to compare, albeit indirectly, the results of randomized controlled trials on overall survival…
Read MoreTumor Treating Fields enhance chemotherapy efficacy by increasing cellular drug uptake and retention in mesothelioma cells
American Journal of Cancer Research 2025 January 15 [Link] Rosy Amodeo, Lavinia Morosi, Marina Meroni, Ezia Bello, Sara Timo, Roberta Frapolli, Maurizio D’Incalci, Monica Lupi Abstract Tumor Treating Fields (TTFields) applied with standard chemotherapy have been approved for the first-line treatment of unresectable pleural mesothelioma (PM), an aggressive malignancy with limited effective therapy options. In…
Read MoreCurrent Status of Staging and Restaging Malignant Pleural Mesothelioma
Seminars in Nuclear Medicine 2025 March [Link] Egesta Lopci Malignant pleural mesothelioma (MPM) is the most frequent aggressive tumor affecting the pleura, accounting for over 38,000 deaths worldwide. It originates from the mesothelial cells and is mostly associated to asbestos exposure. Depending on the extent of the disease, the management of MPM varies from surgical…
Read More